Gracell Biotechnologies to Report Third Quarter 2022 Financials on Monday, November 14, 2022

Rhea-AI Summary

Gracell Biotechnologies Inc. (NASDAQ: GRCL) will release its unaudited financial results for Q3 2022, ending September 30, on November 14, 2022, before U.S. market opens. The company will also provide updates on recent developments. A live audio webcast and conference call will be held at 8:00 AM ET on the same day. Investors can participate via domestic and international dial-ins. A recording of the event will be available for 90 days after the conclusion. Gracell focuses on developing affordable cell therapies for cancer treatment.

SAN DIEGO, Calif., and SUZHOU and SHANGHAI, China, Oct. 31, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that it plans to release unaudited financial results for the third quarter ended September 30, 2022 and provide an update on recent developments prior to the open of the U.S. financial markets on Monday, November 14, 2022. The management team will host a live audio webcast and conference call at 8:00 AM Eastern Time.

Conference call and webcast details:

Monday, November 14, 2022 @ 8:00am ET
Investor domestic dial-in: (800) 715-9871 
Investor international dial-in: +1 (646) 307-1963
Conference ID: 4840587

Live webcast link: https://ir.gracellbio.com/news-events/events-and-presentations

A replay of the webcast will be available on ir.gracellbio.com shortly after the conclusion of the event for 90 days.

About Gracell
Gracell Biotechnologies Inc. ("Gracell") is a global clinical-stage biopharmaceutical company dedicated to discovering and developing breakthrough cell therapies. Leveraging its pioneering FasTCAR and TruUCAR technology platforms and SMART CART^TM technology module, Gracell is developing a rich clinical-stage pipeline of multiple autologous and allogeneic product candidates with the potential to overcome major industry challenges that persist with conventional CAR-T therapies, including lengthy manufacturing time, suboptimal cell quality, high therapy cost and lack of effective CAR-T therapies for solid tumors. For more information on Gracell, please visit www.gracellbio.com. Follow @GracellBio on LinkedIn.

Media contacts
Marvin Tang
marvin.tang@gracellbio.com

Kyle Evans
kyle.evans@westwicke.com

Investor contacts
Gracie Tong
gracie.tong@gracellbio.com

Stephanie Carrington
stephanie.carrington@westwicke.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/gracell-biotechnologies-to-report-third-quarter-2022-financials-on-monday-november-14-2022-301663084.html

SOURCE Gracell Biotechnologies Inc.

FAQ

When will Gracell report its Q3 2022 financial results?

Gracell will report its Q3 2022 financial results on November 14, 2022.

What time is the Gracell conference call?

The Gracell conference call is scheduled for 8:00 AM ET on November 14, 2022.

How can I access the Gracell earnings call?

You can access the Gracell earnings call via a live audio webcast link provided in their press release.

What is the ticker symbol for Gracell Biotechnologies Inc.?

The ticker symbol for Gracell Biotechnologies Inc. is GRCL.

Where can I find more information about Gracell's technology?

More information about Gracell's technology can be found on their official website at www.gracellbio.com.